Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 451.68
DARA's Cash to Debt is ranked higher than
76% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. DARA: 451.68 )
DARA' s 10-Year Cash to Debt Range
Min: 0.16   Max: No Debt
Current: 451.68

Equity to Asset 0.90
DARA's Equity to Asset is ranked higher than
91% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. DARA: 0.90 )
DARA' s 10-Year Equity to Asset Range
Min: -0.14   Max: 0.96
Current: 0.9

-0.14
0.96
F-Score: 4
Z-Score: -0.77
M-Score: -0.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -749.19
DARA's Operating margin (%) is ranked higher than
58% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. DARA: -749.19 )
DARA' s 10-Year Operating margin (%) Range
Min: -186300   Max: -490.33
Current: -749.19

-186300
-490.33
Net-margin (%) -718.89
DARA's Net-margin (%) is ranked higher than
58% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. DARA: -718.89 )
DARA' s 10-Year Net-margin (%) Range
Min: -48680   Max: 432700
Current: -718.89

-48680
432700
ROE (%) -83.61
DARA's ROE (%) is ranked higher than
60% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. DARA: -83.61 )
DARA' s 10-Year ROE (%) Range
Min: -1057.98   Max: 32.95
Current: -83.61

-1057.98
32.95
ROA (%) -73.90
DARA's ROA (%) is ranked higher than
57% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. DARA: -73.90 )
DARA' s 10-Year ROA (%) Range
Min: -354.55   Max: 29.92
Current: -73.9

-354.55
29.92
ROC (Joel Greenblatt) (%) -24312.50
DARA's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. DARA: -24312.50 )
DARA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -23052.75   Max: -125.66
Current: -24312.5

-23052.75
-125.66
EBITDA Growth (%) -42.60
DARA's EBITDA Growth (%) is ranked higher than
56% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. DARA: -42.60 )
DARA' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 49.5
Current: -42.6

0
49.5
EPS Growth (%) -40.10
DARA's EPS Growth (%) is ranked higher than
57% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. DARA: -40.10 )
DARA' s 10-Year EPS Growth (%) Range
Min: 0   Max: 7.3
Current: -40.1

0
7.3
» DARA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

DARA Guru Trades in

DARA Guru Trades in

Q4 2013

DARA Guru Trades in Q4 2013

Jim Simons 157,175 sh (New)
» More
Q1 2014

DARA Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DARA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.90
DARA's P/B is ranked higher than
98% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. DARA: 0.90 )
DARA' s 10-Year P/B Range
Min: 0.02   Max: 12.6
Current: 0.9

0.02
12.6
P/S 6.50
DARA's P/S is ranked higher than
86% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. DARA: 6.50 )
DARA' s 10-Year P/S Range
Min: 0.43   Max: 5843.28
Current: 6.5

0.43
5843.28
EV-to-EBIT -0.01
DARA's EV-to-EBIT is ranked higher than
51% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. DARA: -0.01 )
DARA' s 10-Year EV-to-EBIT Range
Min: -21.2   Max: 0.5
Current: -0.01

-21.2
0.5
Current Ratio 6.58
DARA's Current Ratio is ranked higher than
80% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. DARA: 6.58 )
DARA' s 10-Year Current Ratio Range
Min: 0.69   Max: 25.68
Current: 6.58

0.69
25.68
Quick Ratio 6.47
DARA's Quick Ratio is ranked higher than
81% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. DARA: 6.47 )
DARA' s 10-Year Quick Ratio Range
Min: 0.69   Max: 25.26
Current: 6.47

0.69
25.26

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.26
DARA's Price/Net Cash is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. DARA: 1.26 )
DARA' s 10-Year Price/Net Cash Range
Min: 0.64   Max: 53.27
Current: 1.26

0.64
53.27
Price/Net Current Asset Value 1.22
DARA's Price/Net Current Asset Value is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. DARA: 1.22 )
DARA' s 10-Year Price/Net Current Asset Value Range
Min: 0.64   Max: 49.06
Current: 1.22

0.64
49.06
Price/Tangible Book 1.17
DARA's Price/Tangible Book is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. DARA: 1.17 )
DARA' s 10-Year Price/Tangible Book Range
Min: 0.61   Max: 50.58
Current: 1.17

0.61
50.58
Price/Median PS Value 0.32
DARA's Price/Median PS Value is ranked higher than
93% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. DARA: 0.32 )
DARA' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 941.52
Current: 0.32

0.37
941.52
Earnings Yield (Greenblatt) -10000.00
DARA's Earnings Yield (Greenblatt) is ranked lower than
54% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. DARA: -10000.00 )
DARA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 212.2   Max: 468040.1
Current: -10000

212.2
468040.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PJUF.Germany
DARA Biosciences, Inc., was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.
» More Articles for DARA

Headlines

Articles On GuruFocus.com
PARA GANAR DINERO Jul 15 2012 
DARA Biosciences Inc. Reports Operating Results (10-Q) Aug 13 2010 
DARA Biosciences Inc. Reports Operating Results (10-Q) May 14 2010 
DARA Biosciences Inc. Reports Operating Results (10-Q) Nov 13 2009 
DARA Biosciences Inc. Reports Operating Results (10-Q) Aug 14 2009 
DARA Biosciences Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
Most active Nasdaq-traded stocks Nov 26 2014
DARA BIOSCIENCES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Nov 21 2014
DARA BIOSCIENCES, INC. Financials Nov 19 2014
10-Q for DARA BioSciences, Inc. Nov 07 2014
Progress Continues At DARA Bio Nov 06 2014
DARA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 05 2014
DARA BioSciences Announces Third Quarter 2014 Results Nov 05 2014
DARA BioSciences Announces Third Quarter 2014 Results Nov 05 2014
Q3 2014 DARA Biosciences Inc Earnings Release - After Market Close Nov 05 2014
DARA BioSciences Continues to Support Patient Outreach and Education in Conjunction With Breast... Oct 31 2014
DARA BioSciences Continues to Support Patient Outreach and Education in Conjunction With Breast... Oct 31 2014
DARA BioSciences Announces Date and Time for Announcement of Third Quarter 2014 Results Oct 29 2014
DARA BioSciences Announces Date and Time for Announcement of Third Quarter 2014 Results Oct 29 2014
DARA BioSciences Petitions FDA to Amend Label for Tamoxifen Citrate and Soltamox® to Extend... Oct 29 2014
DARA BioSciences Supports Breastcancer.org to Increase Awareness and Raise Funds to Fight Breast... Oct 24 2014
DARA BioSciences Supports Breastcancer.org to Increase Awareness and Raise Funds to Fight Breast... Oct 24 2014
DARA BioSciences Product Gelclair(R) Attains Market Leadership Position in U.S. Retail Market Oct 14 2014
DARA BioSciences Announces Participation at the Aegis Capital Corporation Healthcare and Technology... Sep 11 2014
DARA BioSciences Announces Participation at the 16th Annual Rodman & Renshaw Global Investment... Sep 03 2014
DARA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK